(Q87146227)
Statements
First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers (English)
Kaku Saito
Hirotaka Nagashima
Kazuharu Noguchi
Kunihiro Yoshisue
Tatsushi Yokogawa
Eiji Matsushima
Takeshi Tahara